ABSTRACT
INTRODUCTION
In the forthcoming years, postgenomic medicine will allow for the enlightenment of the individual genetic predisposition to different diseases, including cancer. People at risk of cancer should benefit from appropriate, effective, and safe prevention approaches if available. Tumor immunoprevention, an obvious option for virus-related tumors, could also become a way to avoid development and progression of genetically determined tumors, provided that relevant tumor antigens will be identified and targeted with no or acceptable side effects (1) (2) (3) (4) (5) .
Mice transgenic for oncogenes are models of human cancer natural history and of genetic cancer predisposition (6, 7) , and can help in assessing whether immunoprophylactic approaches of cancer are effective (1, 3, 8) . Studies on HER-2/neu transgenic murine models have shown that soluble factors (such as cytokines or other immunostimulating agents; Refs. 9, 10) and vaccines based on DNA (11) (12) (13) , peptides (14, 15) , proteins (16) , or cells expressing tumor antigens (17) (18) (19) have a significant preventive activity. Effective immune targeting of HER-2/neu was found in several human and experimental systems (20 -26) . Cancer immunoprevention could also be designed for different tumor antigens (27) . An impressive immunoprevention of HER-2/neu transgenic mammary cancer was obtained through the systemic administration of recombinant interleukin (rIL) 12 combined with a cell vaccine presenting both HER-2/neu antigens and allogeneic MHC H-2 glycoproteins (19) . Such multivalent vaccination strategy required the presence of the three components (rIL-12, HER-2/ neu, and allogeneic MHC) to maintain most HER-2/neu transgenic mice free from mammary tumors up to at least 1 year of age, whereas all of the untreated mice succumbed to mammary cancer within about 20 -25 weeks. Such results encourage pursuing immunoprophylactic approaches for cancer.
In view of a translation to clinics, potential toxicity problems caused by the systemic administration of rIL-12 must be overcome (28 -31) . Other immunostimulatory cytokines, such as IFN-␥, IL-2, and IL-15, could be candidates for immunoprophylactic studies, but they also showed high systemic toxicity (32) . Cytokine gene transduction could be a strategy to obtain cell vaccines able to present both the appropriate antigens and the adjuvant cytokine effect (26, 33) . To verify this approach, in the present study we evaluated the immunopreventive ability of allogeneic HER-2/neu cell vaccines engineered with various cytokines against HER-2/neu transgenic mammary carcinoma.
MATERIALS AND METHODS
Mice. BALB-neuT virgin female mice (H-2 d ), overexpressing the activated rat HER-2/neu oncogene driven by the mouse mammary tumor virus promoter, and IFN-␥ gene knockout BALB-neuT mice were bred and maintained as reported (9, 19) . A female MT mouse (knockout for the immunoglobulin chain gene; Ref. 34 ) on BALB/c genetic background, a kind gift from Dr. Thomas Blankenstein (Max-Dellbruck Center for Molecular Medicine, Berlin, Germany), was crossed with a BALB-neuT male mouse; F 1 male mice were backcrossed with female MT to obtain mice homozygous for the chain knockout allele and heterozygous for the HER-2/neu transgene. B220-positive B cells were routinely monitored by flow cytometry using monoclonal antibody RA3-6B2 (BD PharMingen, San Diego, CA). Experiments were authorized by the local animal use and care committee. Individually tagged virgin females used in the experiments were treated and inspected for mammary tumors as reported previously (9, 19) .
Cells and Transfections. Cells used as allogeneic cytokine-engineered vaccines were derived from mammary carcinomas of FVB-neuN #202 mice (H-2 q ), transgenic for the rat HER-2/neu proto-oncogene (35) . Two HER-2/ neu-positive cell clones (N202.1A and TT12.E2, here referred to as Neu/H-2 q /A and Neu/H-2 q /B), derived from independent tumors, were used as recipient. The following plasmid vectors were used as described previously: BCMGneoIFN-␥ (carrying the murine IFN-␥ cDNA; Refs. 36 Cytokine production by the selected clones was stable for Ͼ3 months of continuous culture. The chosen cytokine-engineered cells showed a decreased s.c. growth in syngeneic hosts compared with nonengineered cells, but not a total rejection, with tumors still occurring in 40 -100% of mice (data not shown). A limited in vivo persistence of the engineered cells was found previously to be a requisite to obtain a good antitumor immune response (40) .
As experimental controls, two other cell lines were transfected with IL-12 genes as reported above. Cell clone N202.1E (here referred to as Neu neg /H-2 q ) was derived from the same mammary cancer originating N202.1A but lacked HER-2/neu expression (35) . HER-2/neu-positive cell clone TUBO (here referred to as Neu/H-2 d ) was derived from a mammary carcinoma of BALBneuT mice (19, 41) . IL-12 transfectants obtained from these cells were named Neu neg /H-2 q /IL12 and Neu/H-2 d /IL12, respectively. Conditions for cell cultures and mitomycin C treatment (to block cell proliferation, when required) and the evaluation of the surface expression of HER-2/neu and class I H-2 q molecules were performed as reported (19, 41) . Vaccination Protocol. Starting at the sixth week of age, BALB-neuT mice entered the vaccination protocol, consisting of 4-week cycles: in the first 2 weeks mice received four twice-weekly i.p. vaccinations with 2 ϫ 10 6 mitomycin C-treated cytokine-engineered cells in 0.4 ml of PBS, followed by 2 weeks of rest. Unless otherwise specified, vaccination cycles were repeated lifelong; in indicated experiments, mice received only the first three vaccination cycles and then were observed for tumor appearance. Vaccination with nonengineered cells, performed with the same schedule as above, was combined to five daily i.p. administrations (50 ng in the first course and 100 ng thereafter) of mouse rIL-12 (kindly provided by Dr. S. Wolf, Genetics Institute, Andover, MA) in the third week, according to the protocol reported previously (19) . Control mice received only the vehicle 0.01% mouse serum albumin (MSA; Sigma Chemical Co., St. Louis, MO). Their tumor progression mirrored that of untreated mice.
Morphological Analysis. Groups of 3 mice were killed at the indicated times. Tissue samples were processed as described previously (42) for histological evaluation or immunohistochemistry. The following antibodies were used: anti-p185 neu (C-18; Santa Cruz Biotechnology, Inc.) and antiproliferating cell nuclear antigen (Ylem, Rome, Italy). Pelt preparation for mammary gland whole mount was performed as described. concanavalin A-induced lymphoblasts was evaluated by a standard 51 Cr release assay and percentage of lysis was calculated as described (39, 43) . Supernatants from MLTC performed as above with a 10:1 splenocyte:tumor cell ratio were assayed for IFN-␥ and IL-4 by ELISA assays (R&D Systems Inc.) as described (19) .
Antibody Response and Immunoprecipitation Assay. Sera were collected from individual mice in experimental groups at different time points and stored at Ϫ80°C. Anti-HER-2/neu total antibodies and subclasses were studied by flow cytometry as reported previously (19) . For immunoprecipitation studies, Neu/H-2 q /A or Neu neg /H-2 q tumor cells were metabolically labeled for 6 h with 100 Ci of 35 S-labeled Cysteine ϩ Methionine mixture (Amersham) in DMEM without methionine and cysteine supplemented with L-glutamine and 3% dialyzed fetal bovine serum. Cells were washed three times in PBS at 4°C and then lysed in lysis buffer containing 1% NP40 for 30 min in ice. After preclearing with protein A-Sepharose, lysates were immunoprecipitated with protein A-Sepharose (Pharmacia) and 15 l of preimmune or vaccinated mice serum or 10 l of anti-HER-2/neu Ab4 monoclonal antibody (Oncogene). Immunoprecipitated molecules were washed and eluted in 1ϫ loading buffer containing 2% SDS, resolved by standard SDS-PAGE on a 10% polyacrylamide gel, and visualized by autoradiography.
Microarray. Mammary glands and tumors were collected from vaccinated and untreated mice at different time points of progression. Total RNA was extracted with TRIzol reagent (Invitrogen) from snap-frozen, pulverized tissue, and its integrity was checked on agarose gel. Biotin-labeled antisense cRNA was prepared according to Affymetrix (Santa Clara, CA) protocol, as reported (44) . Raw data from MAS 5.0 were analyzed with Gene Spring software (Silicon Genetics, Redwood City, CA). Briefly, each measurement was normalized to the median of all of the measurements in that sample, and each gene in each sample was normalized to the median of the measurements of that gene in 6-week samples. Only genes called present and with a signal intensity Ͼ20 in at least 3 samples were retained for additional analysis. Average linkage hierarchical clustering was performed with Genesis software 8 on genes that showed at least a 4-fold difference in the expression level in at least one comparison.
Statistical Analysis. Differences in tumor-free survival curves were analyzed by Mantel-Haenszel test. Tumor multiplicities, and cytokine and antibody levels were compared by Student's t test. Although the low efficacy of the IL-15-engineered cell vaccine may relate to the low secretion rate of this cytokine, it should be underlined that in previous studies IL-15-engineered mammary carcinoma TS/A cells, secreting 0.4 -1.6 ng/ml of IL-15, induced immune-mediated rejection responses when implanted into syngeneic mice, and were active both as prophylactic and therapeutic vaccine against a TS/A challenge (45) . Moreover, the existence of multiple post-transcriptional mechanisms, which down-regulate IL-15 protein synthesis and secretion (46, 47) , prevented the possibility to achieve higher IL-15 secretion rates without altering the mature protein structure. These data show that IL-12 expression engineered into allogeneic HER-2/ neu cells provides a powerful immunopreventive cell vaccine and that IL-12 has the most effective adjuvant activity in comparison to other immunostimulatory cytokines.
RESULTS

Immunoprevention of HER-2/neu
IL-12-Engineered Neu/H-2 q Cell Vaccines. To study the variability between independently obtained cell vaccines, Neu/H-2 q /A/ IL12 cell vaccine was compared with Neu/H-2 q /B/IL12, an IL-12 transfectant derived from an independent HER-2/neu mammary tumor of the same H-2 q transgenic FVB-neuN mice origin (35) . Both engineered cell vaccines highly efficiently halted mammary carcinogenesis, maintaining 83-90% of mice up to 52 weeks of age free from mammary tumors (Fig. 2, A and B) . Vaccines also caused a significant decrease in the number of tumors. IL-12-engineered vaccines ap-peared slightly more effective than allogeneic HER-2/neu cells combined to systemic rIL-12; however, the difference was not statistically significant. As statistical analysis did not show significant differences between the two IL-12-engineered clones, data obtained with Neu/H-2 q /A/IL12 and Neu/H-2 q /B/IL12 will be pooled hereafter. Vaccinated tumor-free mice showed a strong resistance to a challenge with syngeneic Neu/H-2 d mammary carcinoma cells: 65% of vaccinated mice were still tumor-free 30 weeks after challenge, whereas all of the nonvaccinated BALB-neuT mice developed tumors within 4 weeks. (Fig. 2, A and B) .
In some groups of mice vaccination with Neu/H-2 q /IL12 cells was concluded after the first three cycles, to evaluate the degree of prevention of a "short" vaccination schedule (Fig. 2, C and D) . This treatment still determined a highly significant delay in mammary carcinogenesis (P Ͻ 0.001 versus MSA control group), but the proportion of tumor-free mice progressively decreased over time, with a quarter of mice remaining tumor-free at 1 year of age. The comparison of short vaccination protocols including systemic rIL-12 or engineered IL-12 did not yield significantly different results.
Effects of Vaccination on Tumor Progression. A microscopic analysis of mammary glands was first performed by the whole mount technique (Fig. 3) . Untreated controls at 15 weeks of age showed a diffuse hyperplasia with some focal in situ carcinoma that led to the appearance of multiple mammary tumors at 22 weeks (Fig. 3, A and  B) , eventually affecting almost all of the mammary glands (see Fig. 2 ). Vaccination with Neu neg /H-2 q /IL12 did not significantly modify hyperplasia and tumor onset (Fig. 3, C and D) . On the contrary, vaccination with Neu/H-2 q /IL12 led to mammary glands almost devoid of hyperplastic or neoplastic lesions (Fig. 3, E and F) . Similar results were also shown by histological and immunohistochemical analysis. In vaccinated mice, mammary gland ducts were formed by a single layer of epithelial cells lacking the expression of both proliferating cell nuclear antigen and HER-2/neu oncogene product, p185 neu (Fig.  4, D-F) . On the contrary, age-matched untreated mice revealed multifocal mammary carcinomas showing an expansive and invasive growth pattern and formed by highly proliferating (proliferating cell (Fig. 4, A-C) .
Mammary glands from untreated controls and from mice vaccinated with Neu/H-2 q /IL12 cells were collected at 6, 15, 19, and 26 weeks of age, and gene expression profiles were studied. Hierarchical clustering of the differentially expressed genes ( Fig. 5 ; Supplementary Data) showed the overexpression in tumor-bearing samples of two large clusters (denoted as A and C) that mainly group genes induced by HER-2/neu expression or related to tumor progression, and one cluster of genes (B) overexpressed in tumor-negative vaccinated samples, almost exclusively composed by genes related to the immune response. Clusterizing of samples with respect to genes showed that mammary glands bearing multiple focal carcinomas (19 weeks) and macroscopic lobular tumors (26 weeks) clustered together and far apart from 6-week and 15-week (hyperplastic/early neoplastic) mammary glands, whereas mammary tissue from vaccinated mice even at Cell-Mediated and Humoral Responses. To study the immune activities associated with cancer prevention, we examined both cellmediated and humoral responses elicited in BALB-neuT mice by IL-12-engineered allogeneic cell vaccines in comparison to the systemic administration of rIL-12. Activation of spleen cells was studied both by a cytotoxicity assay and by proliferative and cytokine-releasing activity in culture after three cycles of treatment. After in vitro MLTC restimulation, splenocytes from mice vaccinated with Neu/H-2 q /IL12 cells displayed very low cytotoxic activity (Ͻ10%; data not shown) against Neu/H-2 q or Neu/H-2 d tumor cells, in agreement with data obtained previously with the systemic rIL-12-including protocol (19) . However the MLTC-derived lymphoblasts efficiently lysed allogeneic H-2 q splenocytes, indicating that alloreactive CTLs were generated.
Spleen cells from mice vaccinated with Neu/H-2 q cells engineered to release IL-12 (Neu/H-2 q /IL12) or combined with systemic rIL-12 displayed significantly increased spontaneous in vitro proliferation and cytokine production compared with control mice (Fig. 6 ) and mice treated with systemic rIL-12 alone (19) . Vaccines increased production of IFN-␥ and of IL-4. IFN-␥ was released both by CD4 and by CD8 cells, whereas IL-4 was only produced by CD4 cells (data not shown). Proliferation and cytokine release were additionally increased by in vitro restimulation with cells presenting p185 neu (Neu/ H-2 d ), allogeneic MHC glycoproteins (Neu neg /H-2 q ), or both (Neu/ H-2 q ); therefore, a polyclonal activation of the immune response occurred, as can be expected based on the multiple antigenic stimulation. The comparison of the vaccination protocols including systemic or engineered IL-12 showed similar in vitro proliferation activity and cytokine release. It should be noted that similar levels of in vitro proliferation and cytokine release were also found in mice Sera from vaccinated mice were collected after three to four vaccination cycles to study antibodies binding syngeneic Neu/H-2 d cells (Fig. 7) . IL-12-engineered allogeneic HER-2/neu cell vaccine elicited the highest level of serum antibody, significantly higher than those found with any other vaccination protocol, including Neu/H-2 q cells combined with systemic rIL-12 (Fig. 7A) . Such difference was due to a significant increase in IgG2a and IgG3 antibody subclasses (Fig.  7B) . The presence of specific anti-p185 neu antibodies in sera of immune mice was confirmed by immunoprecipitation and SDS-PAGE analysis (Fig. 7C) . Serum from vaccinated mice precipitated from metabolically labeled Neu/H-2 q /A and Neu/H-2 d cell lysates a molecule of the size expected for p185 neu , which was absent in immunoprecipitated molecules from HER-2/neu-negative cells. A molecule of the same size was precipitated by the anti-HER-2/neu Ab4 monoclonal antibody. In addition, preabsorption of Neu/H-2 q /A cell lysates with Ab4 and protein A-Sepharose specifically reduced the intensity of the 185 kDa band precipitated by the immune serum (Fig. 7C) .
Systemic Cytokine Levels Induced by Vaccination. A rationale for the use of IL-12-engineered cell vaccines was to avoid potential systemic toxicity by administered rIL-12 or by IL-12-induced IFN-␥; therefore, we examined serum levels of IL-12 and IFN-␥ in vaccinated mice (Fig. 8) . For both cytokines, levels induced by IL-12-engineered cells showed rapidly transient peaks, approaching at most 100 pg/ml for 1-2 days. Such levels were about 1 order of magnitude lower than those obtained with exogenous rIL-12, which caused cytokine serum concentrations at ng/ml levels for 4 -5 consecutive days. Even considering that vaccination cycles with engineered cells consisted of four injections at 3-4 day intervals, the calculated cumulative cytokine levels and exposure times for the whole treatment were still lower than those of the rIL12-including protocol. These data show that IL-12-engineered vaccines could have a decreased potential toxicity without loss of vaccine efficacy. (Fig. 9, A and B) and was severely decreased in IgM knockout MT HER-2/neu transgenic mice unable to mount an antibody response (Fig. 9, C and D) . The latter mice were still able to produce IFN-␥ in response to the allogeneic stimuli and to IL-12 released by the engineered cell vaccine (data not shown), which explain the residual immunopreventive activity. The results obtained in knockout mice indicate that both IFN-␥ and antibody responses played central roles in the immunopreventive efficacy of IL-12-engineered allogeneic HER-2/neu cell vaccines.
DISCUSSION
Data reported in this article show that a potent immunopreventive cell vaccine against HER-2/neu mammary cancer can be obtained through IL-12 gene transduction into allogeneic HER-2/neu cells. A comparison among various engineered cytokines showed that IL-12 is much more effective than IFN-␥, IL-2, or IL-15. Moreover, engineered IL-12 can substitute for the systemically administered rIL-12, without loss of efficacy and with a lower toxic potential.
Cancer immunoprevention is a fresh and intriguing notion that arose from experimental data showing that immunoprophylactic approaches protect healthy individuals from cancer growth, even in models with a low immunogenicity, compared with the low efficacy of immunotherapeutic approaches in hosts bearing established tumors (1) (2) (3) (4) (5) . The knowledge of individual genetic predisposition to defined cancers will provide the basis to develop tailored immunoprevention treatment. Of course immunoprophylaxis in healthy patients should take in the most consideration the risk:benefit ratio of the treatment, developing strategies with no or very limited potential side effects (3).
IL-12 is a promising adjuvant for cancer and other vaccines (28 -31, 48) . This cytokine polarizes the immune response toward the Th1 type and activates potent antiangiogenic mechanisms, mainly through the induction of IFN-␥ and a cascade of other secondary and tertiary cytokines (29) .
IL-12 is a key cytokine in cancer immunoprevention. Systemic rIL-12 administered alone in healthy mice during the induction of chemical carcinogenesis (49) or the development of HER-2/neu transgenic mammary tumors (9) was able to delay the carcinogenetic process. Antiangiogenic IFN-␥-mediated mechanisms played an important role in delaying both chemical and transgenic carcinogenesis (9, 29, 49, 50) . The combination of systemic IL-12 with an allogeneic antigen-expressing cell vaccine led to an almost complete prevention of HER-2/neu-induced mammary tumorigenesis (19) . In this combined approach the maximal prevention required all of the three components (HER-2/neu, allogeneic MHC antigens, and rIL-12) and was due to the induction of both cellular and humoral immune responses. Although Th1 and Th2 responses were both increased by our vaccine approach, the relative importance of IFN-␥-dependent antibody subclasses for successful cancer prevention indicates that type-1 responses were more important than type-2 (Ref. 19 and present article). Therefore, rIL-12 seems a crucial component for the induction of a full immunoprevention of carcinogenesis. Mice subjected to a lifelong treatment with the three-component vaccine were healthy, with no evident toxicity, and their lifetime almost approached that of nontransgenic parental mice. Such an outstanding result, however, was not amenable to clinical development, because doses of rIL-12 used in murine models are well above the maximum tolerated dose in humans.
The maximum tolerated dose of rIL-12 in humans ranges between 200 and 500 ng/kg for i.v. or s.c. administration (29, 30) . Severe toxic effects that included fever and flu-like symptoms, nausea, fatigue, oral stomatitis, and elevation in liver enzymes were correlated with the induction of IFN-␥ in serum. A slightly higher tolerability was reported for i.p. administration of rIL-12, likely due to the prolonged confinement of IL-12 and IFN-␥ in the peritoneal cavity (51) . Attempts to decrease rIL-12 dose in the prevention of HER-2/neu transgenic mammary cancer showed that minimal doses of systemic rIL-12 that delay tumor formation were still higher than human maximum tolerated dose (52) .
The major activity of IL-12 in our three-component vaccine appeared to be its adjuvant role in the induction of the immune response (19) ; thus, we hypothesized that an IL-12-engineered cell vaccine, able to release the cytokine locally, could attain the same result with a lower toxicity risk. We found that IL-12-engineered allogeneic HER-2/neu cell vaccines elicit the same high level of prevention of HER-2/neu mammary carcinogenesis obtained previously with cells plus systemic rIL-12. The high efficacy of IL-12-engineered cell vaccine with an overall tumor-free survival at 1 year higher than 80% was illustrated by morphological studies and confirmed at the molecular level by the analysis of gene expression profiles. Mice vaccinated with IL-12-engineered cells showed strongly decreased levels of circulating IL-12 and IFN-␥ as compared with mice receiving rIL-12, thus suggesting that a major risk of systemic toxicity (i.e., cytokine serum level) could be avoided or significantly reduced by this gene therapy approach without loss of efficacy.
Data from both morphological and molecular studies indicated that mammary gland "normalization" was an early event, already detectable after three to four vaccination cycles; therefore, we also tested the possibility of shortening the vaccination protocol to the first three cycles, to additionally decrease the potential toxicity of the immunoprophylactic treatment. However, this short protocol only afforded a delay in mammary tumor development; also in this case systemic versus engineered IL-12-including vaccinations showed similar efficacy. Such data also show that periodic boosts of the immune response are necessary to obtain a high-level protection. The possibility, however, that a lighter lifelong vaccination schedule (i.e., by decreasing the number of cell vaccine injections per cycle) could attain the same result remains to be explored.
In conclusion, we showed here for the first time that IL-12-engineered tumor cells can be successfully used as an immunoprophylactic multicomponent vaccine to protect mice from spontaneous genetically determined carcinogenesis.
